

Drugs which require monitoring – Signposting to available guidance

Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information from this beyond its intended use. While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline should not be used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning Groups in NCL.

Document control

Date	Version	Amendments
21/01/2020	V1.0	New document

Document management

Groups / Individuals who have overseen the development of this guidance:	NCL Right Test Right Time Working Group
Groups which were consulted and have given approval:	NCL Shared Care Group
File name:	Drugs which require monitoring – Signposting to available guidance
Version number:	V1.0
Available on:	www.ncl-mon.nhs.uk
Disseminated to:	NCL Trusts and CCGs
Equality impact assessment:	Nil impact identified
NCL Shared Care Group Approval date:	January 2020
Review date:	January 2023

This document is for information on monitoring only. See relevant guidelines for details; contact local Medicines Management Teams for further information

Drug	Source	NCL JFC Guidance Available	SPS Guidance Available?	Other
ACE inhibitors and angiotensin II receptor antagonists	SPS Guidance	x	✓	
Acetylcholinesterase inhibitors – donepezil, galantamine, rivastigmine	SPS Guidance	x	✓	
Amiodarone	SPS Guidance	x	✓	NHS England Guidance - for no new initiations in primary care for any new patient
Antipsychotic agents	SPS Guidance	✓	✓	NCL JFC Factsheet available. Additional information on glucose monitoring and cholesterol/lipid monitoring is also available
Azathioprine	SPS Guidance	✓	✓	NCL JFC Factsheet available. Azathioprine for renal transplant patients is on the red list
Carbimazole	SPS Guidance	x	✓	
Ciclosporin	SPS Guidance	✓	✓	NCL JFC Factsheet available. Ciclosporin for renal transplant patients is on the red list
Corticosteroids (long term oral therapy)	SPS Guidance	x	✓	
Coumarins (including warfarin)	SPS Guidance	x	✓	
DOACs	SPS Guidance	✓	✓	NCL JFC Guidance available but currently being updated.
Digoxin	SPS Guidance	x	✓	
Dronedarone	SPS Guidance	x	✓	NHS England Guidance - for no new initiations in primary care for any new patient. Can only be prescribed under shared care agreement in exceptional circumstances
Eplerenone	SPS Guidance	x	✓	
Hydroxycarbamide	SPS Guidance	x	✓	
Leflunomide	SPS Guidance	✓	✓	NCL JFC Factsheet available
Lithium	SPS Guidance	✓	✓	NCL JFC Factsheet available. Additional information on when increased monitoring is required is detailed in the factsheet
Mercaptopurine	SPS Guidance	✓	✓	NCL JFC Factsheet available. Further information on indications is available in the factsheet
Mesalazine	SPS Guidance	x	✓	

This document is for information on monitoring only. See relevant guidelines for details; contact local Medicines Management Teams for further information

Drug	Source	NCL JFC Guidance Available	SPS Guidance Available?	Other
Methotrexate	SPS Guidance	x	✓	NCL JFC Shared care document available
Mycophenolate	SPS Guidance	✓	✓	NCL JFC Factsheet available
Nitrofurantoin (repeat Rx's)	SPS Guidance	x	✓	Lower Urinary Tract Service is developing guidance
NSAIDS	SPS Guidance	x	✓	PINCER, STOP/START indicators
D-Penicillamine	SPS Guidance	✓	✓	NCL JFC Factsheet available.
Phenytoin	SPS Guidance	x	✓	
Pioglitazone	SPS Guidance	✓	✓	Included information in NCL JFC Antihyperglycaemic agents for Type 2 diabetes guidance .
Propylthiouracil	SPS Guidance	x	✓	
Sirolimus	SPS Guidance	x	✓	See RED list for details - historic shared care arrangements may be in place for patients – prescribers are advised to continue to liaise with the specialist transplant units for monitoring requirements and clinical information
Spirolactone (adjunct in moderate to severe heart failure)	SPS Guidance	x	✓	
Statins	SPS Guidance	✓	✓	NCL JFC Guidance available but currently being updated.
Sulfasalazine	SPS Guidance	✓	✓	NCL JFC Factsheet available.
Tacrolimus	SPS Guidance	x	✓	Monitoring information may be available from a shared care guideline written by the Royal Free Hospital. See RED list for details - historic shared care arrangements may be in place for patients – prescribers are advised to continue to liaise with the specialist transplant units for monitoring requirements and clinical information
Theophylline/aminophylline	SPS Guidance	x	✓	
Thyroxine (levothyroxine)	SPS Guidance	x	✓	
Valproate and sodium valproate	SPS Guidance	x	✓	
Carbamazepine	GP Suggestion	x	x	
Testosterone	GP Suggestion	x	x	